Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Net Cash Flow (2016 - 2025)

International Stem Cell (ISCO) has disclosed Net Cash Flow for 16 consecutive years, with $46000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow fell 78.8% to $46000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$141000.0, a 283.12% decrease, with the full-year FY2024 number at -$358000.0, down 142.32% from a year prior.
  • Net Cash Flow was $46000.0 for Q3 2025 at International Stem Cell, up from -$332000.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $439000.0 in Q2 2023 to a low of -$367000.0 in Q2 2021.
  • A 5-year average of $35842.1 and a median of $76000.0 in 2022 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: tumbled 680.85% in 2021, then surged 352.08% in 2024.
  • International Stem Cell's Net Cash Flow stood at -$334000.0 in 2021, then surged by 122.75% to $76000.0 in 2022, then soared by 107.89% to $158000.0 in 2023, then tumbled by 148.73% to -$77000.0 in 2024, then surged by 159.74% to $46000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Net Cash Flow are $46000.0 (Q3 2025), -$332000.0 (Q2 2025), and $222000.0 (Q1 2025).